GlassScriptPhysician profile
Constantin Carseli
NPI 1255428132
$6,222.07
in general payments reported to CMS, 2019-2025
37 companies · $887 in 2025
The $887 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,010 · 2020: $1,305 · 2021: $1,050 · 2022: $889 · 2023: $587 · 2024: $494 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,967.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $932.35 | 2019-2025 | Synthroid |
| Sanofi-Aventis U.S. LLC | $756.01 | 2019-2024 | |
| Lilly USA, LLC | $649.16 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Novo Nordisk INC | $580.46 | 2019-2025 | Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $385.31 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $378.76 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $240.42 | 2019-2025 | Strensiq |
| Radius Health, INC. | $224.96 | 2019-2022 | |
| Amgen INC. | $199.40 | 2021-2025 | Evenity, Tepezza |
| Ibsa Pharma INC. | $183.45 | 2019-2021 | |
| Abbott Laboratories | $165.20 | 2020-2024 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $159.75 | 2020-2025 | Unithroid |
| Saluda Medical Americas, INC. | $152.22 | 2025 | Evoke |
| Corcept Therapeutics | $148.22 | 2019-2023 | Korlym |
| Medtronic, INC. | $120.89 | 2021-2025 | Minimed 780g |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $106.15 | 2023-2025 | Yorvipath |
| Janssen Pharmaceuticals, INC | $96.56 | 2019-2020 | |
| Horizon Therapeutics Plc | $94.72 | 2022-2023 | Tepezza |
| Xeris Pharmaceuticals, INC. | $85.28 | 2022-2024 | Gvoke Hypopen, Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $56.50 | 2021-2024 | |
| Dexcom, INC. | $54.92 | 2021-2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $54.86 | 2021 | |
| Lifescan, INC. | $49.19 | 2022 | |
| Recordati_rare_diseases_inc. | $45.29 | 2025 | Isturisa |
| Amryt Pharma Holdings LTD | $38.44 | 2022-2023 | Mycapssa |
| Ultragenyx Pharmaceutical INC. | $36.98 | 2022 | |
| Merck Sharp & Dohme LLC | $31.27 | 2019 | |
| Madrigal Pharmaceuticals | $28.38 | 2025 | Rezdiffra |
| Tandem Diabetes Care, INC. | $23.24 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $23.12 | 2025 | Omnipod |
| Kyowa Kirin, INC. | $21.92 | 2025 | |
| Alvogen INC | $20.76 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.63 | 2021 | |
| Currax Pharmaceuticals LLC | $17.25 | 2022 | |
| Embecta Corp. | $17.00 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Eisai INC. | $13.27 | 2020 | |
| Shire North American Group INC | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constantin Carseli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.